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ABSTRAK
Tujuan: mengetahui efektifitas peran probiotik dalam menurunkan peradangan pada pasien perlemakan 
hati non-alkoholik (PHNA). Metode: dilakukan pencarian literatur terstruktur untuk membuktikan apakah 
pemberian probiotik dapat mengurangi inflamasi hati pada PHNA. Hasil: enam artikel ditemukan dan ditelaah 
secara kritis. Semua artikel ini menyimpulkan bahwa probiotik dapat menurunkan peradangan hati, yang 
terlihat dalam penurunan enzim transaminase. Selain itu, probiotik juga menurunkan kandungan lemak dalam 
parenkim hati. Namun, apakah probiotik bermanfaat dalam menurunkan progresivitas PHNA menjadi sirosis 
dan menurunkan mortalitas masih perlu dipelajari oleh penelitian lanjutan. Kesimpulan: probiotik memiliki 
manfaat dalam penanganan PHNA. Probiotik dapat digunakan sebagai salah satu terapi pendamping pada 
kasus perlemakan hati non-alkoholik.
Kata kunci: perlemakan hati non alkoholik, probiotik, inflamasi.
ABSTRACT
Aim: to know the effectiveness of probiotic in reducing hepatic inflammation among non-alcoholic fatty liver 
disease (NAFLD) patients. Methods: we performed literature searching regarding the potential role of probiotic 
in reducing hepatic inflammation among NAFLD patients. Results: six articles were finally critically appraised. 
All six studies had good validity and importance. These studies unanimously reported that probiotic is useful 
in reducing hepatic inflammation, and liver fat content. However, further evidence is needed to show whether 
or not probiotic is beneficial reducing cirrhosis progression and liver-related mortality. Conclusion: probiotic 
owns robust potential to treat NAFLD. Probiotic reduce hepatic inflammation, as shown by the reduction of liver 
aminotransferase, and inflammatory markers. Based on this evidence based report, probiotic is a promising 
adjunct therapy for NAFLD.
Keywords: non-alcoholic fatty liver disease (NAFLD), probiotic, inflammation.
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INTRODUCTION
Non Alcoholic Fatty Liver Disease (NAFLD) 
is a disease characterized by lipid accumulation 
in liver parenchym without any history of 
significant alcohol consumption. It was first 
introduced by Ludwig et al in 1980 and has 
been increasingly recognized as a common liver 
disease afterwards.1,2 The histologic finding of 
NAFLD encompass a wide spectrum of disorder 
from simple steatosis, steatohepatitis and liver 
cirrhosis. In the last two decades, NAFLD 
has been recognized as the most common 
liver disease in western countries. NAFLD 
affects 10% to 24% of the general population 
and the number increases up to 74% in obese 
population.3,4 Indonesia is one of the high 
prevalence countries of NAFLD. Lesmana CRA 
et al.5 reported fatty liver was found in 51% of 
patients coming for medical check up.
To be defined as Non-alcoholic steatohepatitis 
(NASH), the liver should meet other criterias 
in addition to the accumulation of fat. The 
histological diagnosis of NASH requires the 
finding of  hepatocyte injury (manifest by swollen 
or ‘ballooned’ cells),  an inflammatory infiltrate 
(predominantly neutrophils) with or without 
fibrosis and it typically distributed perivenular/
pericellular. As many as  50% of  NASH patients 
develop liver fibrosis, 15% would develop 
cirrhosis, and 3% may progress to terminal liver 
failure requiring liver transplantation.6,7
Certain metabolic risk factors have been 
strongly linked to NAFLD. The association 
between obesity, diabetes mellitus (insulin 
resistance) and dislipidemia with NAFLD 
has been well documented. As the amount of 
obesity and diabetes cases increase, so do their 
complications. Therefore the prevalence of 
NAFLD is expected to increase.6 Besides insulin 
resistance and oxidative stress, intestinal flora 
has an important role in the pathogenesis of 
NAFLD. Although the exact mechanism remains 
unknown, small intestinal bacterial overgrowth 
(SIBO) is postulated to induce inflammation 
through the production of cytokine.8
There is currently no effective therapy for 
NAFLD. However as insulin resistance and 
oxidative stress are the two underlying culprits 
of NAFLD, therapy targeted on these particular 
step of pathogenesis is proved to be effective and 
promising.  One novel therapy that has gained 
so much attention lately is probiotic. Probiotic 
works through its effect in manipulating 
commensal intestinal flora. Whether or not 
probiotic can give beneficial effects for NAFLD 
patients needs to be further investigated.
CLINICAL QUESTION
A 47-year old man came to the emergency 
room with a complaint of general weakness since 
one week before hospital admission. He also 
felt very thirsty and urinate a lot for the last one 
week. He felt nauseous and vomited a few times 
before hospital admission. He did not have any 
history of diabetes and hypertension. He denied 
any alcohol consumption.
In the emergency room, blood glucose 
meassurement was 640 mg/dl with keton level 
of 4.1. Blood gas analysis showed consistent 
result of metabolic acidosis, and the diagnosis 
of diabetic ketoacidosis (DKA) was made. The 
patients was then  resucitate according to DKA 
protocol. Another laboratory examinations were 
as follow: Hb: 11.1 g/dl, leukocyte 11,000/µl, 
platelet count: 151,000/µl, and HbA1c: 12.3. 
The liver aminotransferase level was sligthly 
increased, aspartate aminotransferase: 57 U/L, 
alanin aminotransferase: 96 U/L. Hepatitis virus 
serology was negative. Bedside ultrasonography 
was performed with the result of bright liver, 
consistent with fatty liver disease, therefore the 
diagnosis of nonalcoholic fatty liver disease 
(NAFLD) was made.
After the acute period of ketoacidosis was 
succesfully managed, the patient was then 
transfered to the inpatient ward for further 
management. Apart from the treatment for his 
diabetes, we would like to give this patient an 
evidence based treatment for NAFLD. Apart 
from lifestyle modification, probiotic is an 
emerging therapeutic approach for NAFLD. 
To further confirmed probiotic efficacy in 
treating NAFLD, we performed an evidence 
based searching to justify the administration of 
probiotic among NAFLD patients.
Is probiotic administration effective to 
reduce hepatic inflammation among patients 
with NAFLD?
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• P (Population):Patients with NAFLD
• I (Intervention): The administration of 
probiotic
• C (Comparison): Placebo or lifestyle 
modification
• O (Outcome) :  Liver  t ransaminase 
improvement, cirrhosis progression, 
mortality.
METHODS
The search was conducted on PubMed,® 
Google scholar®, Proquest® on  9th November 
2015, and 2nd December 2015 respectively, 
using the keywords ‘NAFLD’, ‘probiotic’, 
‘transaminase’, ‘mortality’ along with its 
synonyms and related terms (Table 1). Search 
strategy, the inclusion and exclusion criteria are 
shown in Figure 1.
Table 1. Search strategy used in PubMed, Google scholar and Proquest (Conducted on November 9th 2015, and December 
2nd 2015)
Database Search terms Results
Pubmed (9th 
November 2015)
(((("probiotics"[MeSH Terms] OR "probiotics"[All Fields] OR "probiotic"[All Fields]) 
AND ("non-alcoholic fatty liver disease"[MeSH Terms] OR ("non-alcoholic"[All Fields] 
AND "fatty"[All Fields] AND "liver"[All Fields] AND "disease"[All Fields]) OR "non-
alcoholic fatty liver disease"[All Fields] OR "nafld"[All Fields])) OR nash[All Fields]) 
AND ("mortality"[Subheading] OR "mortality"[All Fields] OR "mortality"[MeSH 
Terms])) OR ("transaminases"[MeSH Terms] OR "transaminases"[All Fields] OR 
"aminotransferase"[All Fields]) AND (Clinical Trial[ptyp] AND "loattrfull text"[sb] AND 
"2010/11/16"[PDat] : "2015/11/14"[PDat])
1475
Google scholar (9th 
November 2015)
NAFLD  NASH Probiotic  transaminase mortality cirrhosis
242
Proquest (2nd 
December 2015)
pub(probiotic) AND pub(fatty liver or nash) AND pub(transaminase) OR ab(mortality)
952
NAFLD Probiotic Transaminase
Pubmed Google scholar
1475 242
Screening title abstract
Filtering double
6
6
Screening title abstract
Full text availability
Useful: 6
Filter:
Clinical Trial,
Review, Full
text, published
in the last 5
years, Humans,
English
 Search date:
9
th
November 2015
2
nd
December 2015
10 4
Mortality
Exclusion:
Not fit with
PICO,
commentary
article, guideline
Five clinical trials:
Wong et al
9
Malaguarnera et al
10
Aller et al
11
Shavakhi et al
12
Eslamparast T et al
13
One meta-analysis:
Ma et al
14
Proquest
952
20
Figure 1. Flowchart of search strategy
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RESULTS
Table 2. Critical appraisal of the useful randomized controlled trials based on criterias by centre of evidence medicine 
University of Oxford
Articles
Validity Applicability
Levels of evidence*
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Wong et al10 + + + - + + + + + 1B
Malaguarnera et al11 + + + + + + + + + 1B
Aller et al12 + + + + + + + + + 1B
Shavakhi et al13 + + + + + + + + + 1B
Eslamparast T et al14 + + + + + + + + + 1B
+ stated clearly in the article; - not being done; ? not stated clearly.
*Levels of evidence based on The Oxford Centre of Evidence-based Medicine
Table 3. Critical appraisal of the meta-analysis
Appraisal questions Ma et al14
Validity What question did the systematic review address? +
Is it unlikely that relevant studies were missed? +
Were the inclusion criterias appropriate? +
Were the included  studies valid? +
Were the results similar from study to study? +
Relevance Patient +
Intervention +
Comparison +
Outcome +
Importance The result of this study is summarized in table 5
+ stated clearly in the article; - not being done; ? not stated clearly;
* Levels of evidence based on The Oxford Centre of Evidence-based Medicine
DISCUSSION
Nonalcoholic Fatty Liver Disease (NAFLD) 
is a common liver disease worldwide. 
This phenomenon is partly influenced by 
environtment factors superimposed on genetic 
factors. Component of the metabolic syndrome, 
which includes obesity, insulin resistance and 
hypertension are some important risk factors 
of NAFLD. The multiple hit hypothesis has 
been the leading theory of the pathogenesis of 
NAFLD. The first hit of insulin resistance would 
make liver cells vulnerable to second hit in the 
form of oxidative stress. These hits would lead 
to liver fibrosis and cell death.2
Recent evidence showed the relation between 
intestinal bacterial overgrowth with NAFLD 
progression. Intestinal bacterial overgrowth 
increase hepatic oxidative stress by increasing 
endogenous ethanol production and releasing 
bacterial lipopolysaccharide (LPS). Both 
ethanol and bacterial LPS could stimulate 
inflammatory cytokine production, one of which 
is TNF-α by hepatocytes and kupffer cells. As 
intestinal bacteria plays an important role in 
the progression of NAFLD, one obvious way 
to control the development of NAFLD is by 
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Table 4. Summary of the RCTs’ result
No Author Pts 
Number
Follow-up Types of probiotic Control Result
1. Wong et al10
20 
NASH 
patients
6 months
Probiotic formula 
containing Lactobacillus 
plantarum, 
Lactobacillus delbruckii 
ssp. Bulgaricus, 
Lactobacillus 
acidophilus, 
Lactobacillus 
rhamnosus, 
Bifidobacterium bifidum
Lifestyle 
modification
The administration of probiotic 
reduce IHTG from 22.6 ± 8.2% 
to 14.9 ± 7.0% in the probiotic 
group (mean reduction 7.7%, 
95% confidence interval 0.7% 
to 14.7%, P=0,034). Liver 
aminotransferase is also reduced 
significantly in the probiotic 
group. The use of probiotics was 
not associated with changes 
in body mass index, waist 
circumference, glucose and lipid 
levels.
2. Malaguarnera et al11
66 
NASH 
patients 
24 weeks Bifidobacterium longum with FOS
Placebo+ 
lifestyle 
modification
The administration of probiotic 
significantly reduce liver 
aminotransferase  AST (109 
± 23.2 to 39.4 ± 28.2 p<0.05), 
LDL cholesterol (3.91±0.77 to 
3.07±0.61, p<0.001), CRP (7.0 
± 3.4 to 4.1 ± 3.1, p<0.05) and 
TNF-α (1.28±0.28 to 0.83 ± 0.36, 
p<0.001)
3. Aller et al12
28 
NAFLD 
patients
3 months
Lactobacillus 
bulgaricus, 
Streptococcus 
thermophiles
Placebo 
Probiotic administration improved 
liver alanine aminotransferase 
level (67.7 ± 25.1 to 60.4 ± 
30.4 UI/L, p < 0.05), aspartate 
aminotransferase activity (41.3 
± 15.5 to 35.6 ± 10.4 UI/L, p 
< 0.05) and gammaglutamine 
transferase levels (118.2 ± 63.1 
to. 107.7 ± 60.8 UI/L, p<0.05)
4. Shavakhi A et al13
64 
NASH 
patients
6 months
Metformin 2x500mg/ 
day + 2 tablets of 
protexin
Metformin 
2x500mg + 2 
placebo tablets
The administration of metformin 
and probiotics provide greater 
reduction in terms of liver 
aminotransferase (ALT level at 
the end of treatment: 45.2 ±32.5  
vs 112.5±68.7, p<0.001). There 
was significant improvement 
in liver radiological image as 
documented by USG in the 
probiotic group.
5. Eslamparast T et al14
52 
NAFLD 
patients
28 weeks 2 tablets of protexin Placebo
There was significant 
reduction in terms of ALT level, 
γ-glutamyltransferase, TNF-α
IHTG: intrahepatic triglyceride content; FOS: fructo-oligosaccharides; ALT: alanine aminotransferase; AST: aspartate 
aminotransferase;LDL: Low Density Lipoprotein ; CRP: C-Reactive Protein; TNF-α: Tumor Necrosis Factor-α; USG: 
Ultrasonography
Protexin (made by Science and nature in balance Co, UK) contained: Lactobacillus acidophilus 1 × 108 CFU, Lactobacillus 
casei 5 × 108 CFU, Lactobacillus rhamnosus 7.5 × 107 CFU, Lactobacillus bulgaricus 1.5 × 108 CFU, Bifidobacterium breve 5 
× 107 CFU, Bifidobacterium longum 2.5 × 107 CFU, Streptococcus thermophilus 5 × 107 CFU, fructooligosaccharides 350 mg.
Table 5. Result of meta-analysis
Author Study included 
in the analysis
Total 
patients
Result
Ma et al15 Four studies 134
The use of probiotic is associated with reduction of liver aminotrasnferase (mean 
difference -23.71,95%CI: -33.46 to -13.95, P<0.00001) , total cholesterol (-0.28, 
95%CI: -0.55 to -0.01, P = 0.04), TNF-  (-0.32, 95%CI: -0.48 to -0.17, P<0.0001). 
Most of the result showed no heterogeneity
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manipulation of the intestinal bacteria.8
One novel way to manipulate intestinal 
bacteria is by the administration of probiotic. 
Although the exact mechanism of probiotics 
in the treatment of NAFLD is incompletely 
understood, it is thought that probiotic interfere 
with NAFLD progression through its effect in 
eradicating pathogenic bacteria in the intestine. 
Probiotic also reduce ethanol production and 
reduce inflammation by altering cytokine 
signaling.9
After a thorough searching, six articles 
were finally critically appraised. All six studies, 
five studies were randomized controlled trials 
and one article was meta-analysis, have good 
validity, importance and applicability as shown 
in Table 2 and 3. These studies also matched our 
clinical question. Each of these studies provide 
different types of endpoint including liver 
aminotransferase, lipid profile, inflammatory 
marker, and liver radiological improvement.
Three clinical trials appraised in this report 
(Wong et al10, Malaguarnera et al11 and Aller et 
al12) were also included in the meta analysis. 
However, since these three studies provide 
interesting end points, we still included these 
studies in our appraisal. The importance of 
treatment effect can not be calculated in the form 
of relative risk due to the variable used in this 
trials are numerical data. Instead, we showed 
the mean difference in every trials, with their 
respective confidence interval.
All six studies reported significant reduction 
of liver enzymes (either ALT, AST or both) 
after the administration of probiotic. Beside 
the reduction of liver enzymes, inflammatory 
cytokines, one of which is TNF-α, were also 
reduced. TNF-α plays an important role in 
inducing hepatic inflammation, which is 
postulated to be the underlying process of 
NAFLD progression into cirrhosis.
Wong et al reported that probiotic reduce 
intrahepatic triglyceride content, as meassured 
by proton magnetic resonance spectroscopy 
(p:0.034).  Proton magnetic  resonance 
spectroscopy is one of the most accurate 
non-invasive test for liver fat. Therefore this 
observation is a reliable measure of liver fat after 
probiotic administration.10
As insulin resistance play an important role 
in NAFLD patophysiology, metformin is often 
prescribed among NAFLD patients. Shavakhi 
A et al13 reported that probiotic enhance the 
effect of metformin in terms of reduction of liver 
aminotransferase and improve liver radiological 
image as documented by USG.14
One meta-nalysis by Ma et al15 further 
support the beneficial effect of probiotic for 
NAFLD treatment in terms of reduction of 
aminotransferase, improvement of cholesterol 
level and inflammatory markers (TNF-α). We 
also explore for heterogeneity in this meta-
analysis and most of the result showed no 
heterogeneity.
One study performed by Loguercio et 
al is not included in this appraisal, due to 
the difference in patients characteristics. 
However, this study provide additional important 
information that the beneficial effect of probiotic 
(VSL#3) extend beyond NAFLD patients. This 
study also investigate the efficacy of probiotic 
administration among patients with alcoholic 
liver cirrhosis, and cirrhosis patients with 
hepatitis C. The administration of probiotic 
reduce lipid peroxidation, which is a key 
component of liver steatosis in patients with 
NAFLD and alcoholic liver cirrhosis. But limited 
effect was observed in patients with hepatitis C.16
TNF-α is a well-established marker for 
inflammation. Most of these studies showed 
consistent result that probiotic reduce the level of 
TNF-α among NAFLD patients. Whether or not 
the level of TNF-α is correlated with the degree 
of liver fibrosis is studied by Lesmana et al17. 
According to this study, increased TNF-α level 
was associated with a more severe fibrosis stage 
among NASH patients. So reduction of TNF-α 
is logically linked to reduction of inflammatory 
condition in the liver, and in the long run, would 
hopefully reduce the progression from NAFLD 
to liver cirrhosis.
Collectively, these unanimous result confirms 
previous animal studies on the potential role of 
probiotic as NAFLD treatment. There were 
multiple animal studies that reported beneficial 
effect of probiotic in improving lipid profile, 
and liver fat content.9 Although all these studies 
reported similar finding that probiotic has 
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potential therapeutic role for NAFLD, cautious 
intepretation of this result is warranted. All 
these studies are relatively small, with a limited 
period of follow up. Another question need to 
be addressed in future studies is the type of 
probiotic can be used. There is currently no 
consensus regarding the strain and the amount 
of bacteria that would produce beneficial effect 
in the treatment of NAFLD.
Is the result of these studies can be applied 
to our case scenario? First, the characteritics 
of our patients match the characteristics of two 
studies performed by Malaguarnera M et al11 
and Wong et al10. Our patient had elevated level 
of liver aminotransferase, negative for hepatitis 
markers, and did not consume alcohol for the last 
six months. So, the result of these studies can be 
applied in our scenario.
Regardless of all these positive findings, 
all the endpoints in these studies are surrogate 
outcome, not hard endpoint (eg. mortality). 
Surrogate markers, like inflammatory markers 
or liver enzymes, are postulated to be related in 
the progression of NAFLD into cirrhosis. So, it 
is logical to assume that the reduction of these 
surrogate markers would translate into reduction 
of cirrhosis, or liver related-mortality.  However, 
it may be premature to think that inflammatory 
parameters improvement is equivalent to 
hard end point benefits, without confirmatory 
data. Whether or not probiotic improve liver 
histology is also yet to be determined. Based on 
our literature searching,  there has not been any 
published clinical trials that study the beneficial 
effect of probiotic in improving liver histology, 
as proven by liver biopsy.
Probiotic administration is a potential 
therapeutic approach, with the caveat that there is 
a lack of published robust clinical trials regarding 
its efficacy in reducing cirrhosis progression 
or liver related mortality. Future studies with a 
larger population and longer period of follow 
up would hopefully answer some lingering 
questions such as, whether or not probiotic 
provide hard endpoint benefit among NAFLD 
patients. Second, what is the best strain, the right 
dosage, and the duration of treatment required to 
produce significant beneficial effect.
An effective therapy for NAFLD is the current 
unmeet need. Since probiotic is affordable, 
widely available and safe, this novel therapy is 
a potential approach in the treatment of NAFLD. 
Based on existing evidence, probiotic can be used 
as an adjunct therapy for NAFLD. 
CONCLUSION
Currently, there has not been any effective 
treatment for NAFLD. Probiotic has a robust 
potential in the treatment of NAFLD. Probiotic 
reduce hepatic inflammation, as shown by 
the reduction of liver aminotransferase, and 
inflammatory markers. Further evidence is needed 
to show whether or not probiotic is beneficial in 
terms of cirrhosis progression and liver-related 
mortality. Probiotic is widely available, safe 
and relatively affordable, therefor probiotic is a 
promising  adjunct therapy for NAFLD.
REFERENCES
1. Angulo P. Nonalcoholic fatty liver disease. N Engl J 
Med. 2002;346:1221-31.
2. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty 
liver disease. CMAJ. 2005;172:899-905.
3. Bedogni G, Miglioli L, Masutti F, Tiribelli C, 
Marchesini G, Bellentani S. Prevalence of and risk 
factors for nonalcoholic fatty liver disease: the dionysos 
nutrition and liver study. Hepatol. 2005;42:44-52.
4. Targher G, Day CP, Bonora E. Risk of cardiovascular 
disease in patients with nonalcoholic fatty liver disease. 
N Engl J Med. 2010;363:1341-50.
5. Lesmana CRA, Pakasi LS, Inggriani S, Aidawati ML, 
Lesmana LA. Development of non-alcoholic fatty liver 
disease scoring system among adult medical check-
up patients: a large cross sectional and prospective 
validation study. Diabetes Metab Syndr Obes. 
2015;8:213-8.
6. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic 
fatty liver disease a feature of the metabolic syndrome. 
Diabetes. 2001;50:1844-50.
7. Collantes R, Ong JP, Younossi ZM. Nonalcoholic fatty 
liver disease and the epidemic of obesity. Cleve Clinic 
J Med. 2004;71:657-64.
8. Medina J, Fernancez-Salazar LI, Garcia-Buey L, 
Moreno-Otero R. Approach to the pathogenesis and 
treatment of nonalcoholic steatohepatitis. Diab Care. 
2004;27:2057-66.
9. Nursalim A, Hasan I. Update 2014: the role of probiotic 
in non-alcoholic fatty liver disease, an evidence based 
approach. Indones J Gastroenterol Hepatol Dig Endosc. 
2013;14:103-8.
10. Wong VWS, Wong GLH, Chim AML, et al. Treatment 
of nonalcoholic steatohepatitis with probiotics. A proof 
333
Alvin Nursalim                                                                                                                       Acta Med Indones-Indones J Intern Med
of concept study. Ann Hepatol. 2013;12:256-62.
11. Malaguarnera M, Vacante M, Antic T, et al. 
Bifidobacterium longum with fructo-oligosaccharides 
in patients with non alcoholic steatohepatitis. Dig Dis 
Sci. 2012;57:545–53.
12. Aller R, De Luis DA, Izaola O, et al. Effect of a probiotic 
on liver aminotransferases in nonalcoholic fatty liver 
disease patients: a double blind randomized clinical 
trial. Eur Rev Med Pharmacol Sci. 2011;15:1090-5.
13. Shavakhi A, Minakari M, Firouzian H, Ferns G. Effect 
of a probiotic and metformin on liver aminotransferases 
in non-alcoholic steatohepatitis: a double blind 
randomized clinical trial. Int J Prev Med. 2013;4:531-7.
14. Eslamprast T, Poustchi H, Zamani F, Sharafkhah 
M, Malekzadeh R, Hekmatdoost.  Synbiotic 
supplementation in nonalcoholic fatty liver disease: 
a randomized, double-blind, placebo-controlled pilot 
study. Am J Clin Nutr. 2014;99:535–42.
15. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects 
of probiotics on nonalcoholic fatty liver disease: a 
meta-analysis. World J Gastroenterol. 2013;19:6911-8.
16. Loguercio C, Federico A, Tuccillo C, et al. Beneficial 
effect of a probiotic VSL#3 on parameters of 
liver dysfunction in chronic liver diseases. J Clin 
Gastroenterol. 2005;39:540-3.
17. Lesmana CRA, Hasan I, Budihusodo U, et al. 
Diagnostic value of a group of biochemical markers 
of liver fibrosis in patients with non-alcoholic 
steatohepatitis. J Dig Dis. 2009;10:201-6.
334
